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Abstract 
Resveratrol is a natural occurring molecule, which has shown promising effects in animal 
models.  Even though a lot of studies have been done on resveratrol, information regarding 
which genes are activated by resveratrol, which causes change to the cells size, is still missing. 
The aim of our study is to examine the cellular effects of resveratrol on growth factor of cell size 
with the modulating role, tempering with the mTOR cascade and SIRT1 enzymes. Our results 
have indicated that cellular enlargement is tightly connected SIRT1. This was found when the 
cell was treated with resveratrol and while either SIRT1 or mTOR was inhibited. Our 
experiments suggest that resveratrol is increasing the cell size via activation of the silent 
regulator gene (SIRT1).  
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Foreword 
Resveratrol is a natural polyphenol which have been given a lot of attention lately on 
web and media and is showing possible future uses proposing various health benefits (1). As the 
mechanism of resveratrol is being studied, more knowledge about its effect on the cell has 
been acquired. The attentions given to resveratrol may not be so surprising, considering the 
rapid statistical increase in diseases like cancer, diabetes and also lifestyle related problems 
such as obesity (2)(3)(4).  Resveratrol has been suggested to possess valuable medical potential 
such as extending the life of cancer suffering patients. Resveratrol was suggested to reduce the 
aging effect in human, the effects of diabetes and cardiovascular disorders (5) (6) (7). However, 
there have been some questions on whether resveratrol really possess some of these qualities 
like cancer, diabetes and obesity reduction.  
The scientific literature show that resveratrol is activating the Sirt1 enzyme but also modulate 
the mTOR signaling cascade. The resveratrol induction of cell enlargement in human epithelial 
cells may depend on the SIRT1-mTOR axis: 
Our hypothesis is therefore 
• That resveratrol modulate the cell size via SIRT1 enzyme activities. 
Figure 1 is suggesting a model for the effect of resveratrol on cell size, involving mTOR cascade 
and SIRT1 enzyme as crucial players.  
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Figure 1: Simple drawing of the possible connections between the SIRT1 enzyme and 
mTOR cascade. From scientific literature we have found there is a connection between 
resveratrol and SIRT1, a relationship between mTOR and the cell size as well as a link 
between resveratrol and the cell size. Those connections are marked with a black line. 
The green lines indicate possible connections, which will be researched in this study, by 
inhibition of SIRT1 (with EX-527) and mTOR (with rapamycin)  
 
 
The aim of our study is to examine the cellular effects of resveratrol on cell size with the 
modulating role by mTOR cascade and SIRT1 enzymes. 
 Therefore, the focus of our experiment is to study the mechanism of resveratrol’s 
cellular activities in connection with mTOR and SIRT1 genes in human epithelial colon cancer 
cells (DLD-1). We will monitor the change in cell size and numbers in the following stages: when 
the inhibitor of mTOR (rapamycin) is added to the cell culture, when the inhibitor of SIRT1 (EX-
527) is added, when they are added with resveratrol, and when no inhibitor is added. The 
possible effects on cell size and numbers will serve as an indicator to which genes are activated 
by resveratrol, and which pathway it takes.  
Based on the knowledge we got before the experiment we expect the following 
outcome from our rapamycin treatment: when the cells are treated with rapamycin, it is 
expected that the cell size will be unaffected as mTOR is inhibited. When the cells are treated 
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with resveratrol it is expected that the cell size is increased. However, when the cells are 
treated with a combination of resveratrol and rapamycin is expected to be unaffected in size. 
While in our EX-527 experiment we expected that the effect of resveratrol will be suppressed in 
the combinatory effect of EX-527 and resveratrol. We assumed that in the treatment with EX-
527 alone that no change in the cell size will be observed.   
 
We will have a brief investigation on cancer and age prolongation in connection to 
resveratrol, as SIRT1 can mimic the effect of caloric restriction, which has shown extended 
lifespan in mice, while mTOR is responsible for the regulation of protein synthesis and cell 
proliferation.  
Due to the scope of our project, we will not be going into the details of all the suggested 
health promoting effects of resveratrol therefore less emphasis will be placed on other 
resveratrol activities such as cardiovascular disease prevention, obesity, oxidative stress, life 
extension and cancer treatment.  
This report is written as manuscript of a scientific paper to be submitted for of the 
journal PLoS ONE. Our report will be based on the guideline of this scientific paper publication, 
as they only will accept systematic reviews/ meta-analysis, and submissions describing methods 
and software. Furthermore PLoS ONE will not accept publication that already has been 
published elsewhere.  Experiments and statistics needs to be described in sufficient detail. The 
later requirement is not fulfilled in this study.  
The PLoS ONE Manuscript Guidelines can be found on the web at: 
http://www.plosone.org/static/guidelines.action;jsessionid=7973D7C1C924CDC97E787521FC686939.   
 
Words marked with asterisks are defined in the glossary, which can be found in the end 
of this study. 
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Introduction 
 
The scientific focus on resveratrol having a health promoting effects was initiated in 1992 (8) by 
the observation that human is exposed to resveratrol as a component found in red wine. 
Further, the study of Jang et al. (1997) (9) strongly suggested resveratrol having cancer 
preventive anti-mutagenic effect, which boosted the interest very strongly. Considering the 
predictions made by Bray et al. (2012) (2) the rapid increase in cancers forces humans to test all 
compounds having possible anti-carcinogenic effects. 
 
Resveratrol and cancer 
Cancer is occurring on the single cell level, because of biological, physical or chemical 
factors. Disruption in the gene regulation/expression or directly in the DNA can cause cancer. 
Cancer results from genetic changes that affect the cell cycle, which cannot be controlled. 
 
Experiments has been done to test the resveratrol`s efficacy in inhibiting the growth of 
skin cancer (10) and the result of this experiment shows that application of resveratrol to 
hairless mice was enough to inhibit the ultraviolet B mediated photo toxicity and skin cancer 
(11). 
 
Resveratrol may also have inhibitory effects on a gastric tumor (12). It also shows that 
treatment with resveratrol not only reduced the size of tumors but also suppressed the 
development of the cancer in mouse. 
 
Resveratrol has been suggested to possess valuable medical potential such as extending 
the life of cancer suffering patients, by reducing the number of carcinogenic cells and by 
minimizing the cell proliferation as well. Resveratrol is believed to inhibits all three phases of 
malignant tumor development: initiation, promotion and progression (13) 
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Cell size  
The cell size is a factor that can be observed from microscope or size measuring devices. 
The meaning cell growth is the accumulation of mass, resulting in cellular enlargement. Cells do 
grow during every differentiation cycle (division). Furthermore cells that stop dividing continue 
to grow to reach optimal size (14).  
 
mTOR (Mammalian Target of Rapamycin) 
TOR signaling (Target of rapamycin) has a role in various growth-related up/down 
regulation-mechanisms in yeast, and yet also in higher eukaryotes (15). This old protein, and 
the signaling network behind it, has been well conserved from yeast to human (16). The 
mammalian target of rapamycin, mTOR is a serine-threonine kinase which regulates cell 
growth, proliferation, homeostasis and cellular metabolism, via controlling DNA-transcription, 
ribosome and protein synthesis (17)(18). mTOR is a part of two different multiprotein 
complexes (cascades) mTORC1 and mTORC2, which differs in subunit  composition and 
biological function.  
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Figure 2: Description of mTOR cascade in details, and how it regulates cell growth and 
proliferation, the focus of this figure will be placed on the outcome and income of mTOR 
cascade) Figure from (15) 
 
mTORC1 is a major regulator of cell growth and metabolism, promoting numerous 
anabolic processes*, including biosynthesis of proteins, lipids, organelles but  also 
mitochondrial metabolism and biogenesis. This first complex of mTOR also limits catabolic 
processes*, such as autophagy*. mTORC1 includes intracellular and extracellular signaling 
pathways which effects: growth factors, energy status, oxygen levels and regulation by amino 
acids (17). 
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 Most of the data regarding mTOR has been gathered from the use of the mTOR 
inhibitor, rapamycin (17). However, some reports suggest that important mTORC1 functions 
(protein synth may be resistant to the inhibition by rapamycin (17) (19). 
 
 mTORC2 promotes Akt/PKB*, and is responsible for cell survival, as it organizes the 
actins* in the cytoskeleton, enabling cellular adherence, communication, and order. mTORC2 is 
unaffected by rapamycin, and will consequently still preserve its effect. The signaling pathways 
that lead to the activation of mTORC2 are still unclear, and insufficient documentation has been 
made about the functions of mTORC2 (17). 
 
Rapamycin (mTOR inhibitor) 
Rapamycin is also known as sirolimus. Rapamycin inhibits mTOR, mTORC1 and mTORC2, 
according to Lamming et al. (2012) (20) the most beneficial effects of rapamycin comes from 
inhibiting mTORC1 which e.g. includes life-lengthening in animal studies, while disruption of 
mTORC2 produces decreased glucose tolerance and insensitivity to insulin as seen in diabetics.  
 
SIRT1 
 
SIRT1 is a silent information regulator, and one of the seven sirutin genes, SIRT1 is 
regulating proteins and silencing genes, by NAD+* dependent deacetylation*. This enzyme 
seems to play an important role in an organism’s response to certain types of stress, toxicity 
and calorie restriction (21). 
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As high caloric intake from food, excess the body’s need, this phenomenon accounts for 
the current rise of metabolic disorders in human (23). SIRT1 seems to be activated when cells 
are submitted to a certain caloric restriction (CR) diet. CR may promote life span, and increased 
disease protection (23). The molecular effects of SIRT1 reside in the nucleus, where it 
deacetylates p53*. This deacetylation by SIRT1 prevents cellular senescence*, and inducing 
apoptosis* by DNA damage and stress (24).   
 
Because of different functions on diverse array of proteins, SIRT1 is assumed to be 
involved in metabolic responses and processes that influence many aspects of human function; 
as longevity, obesity, cancer and other age related diseases. (25) 
 
Ex-527 (SIRT1 inhibitor) 
Ex-527 is a selective inhibitor of SIRT1, it does only inhibits the other sirtuins at very high 
concentrations (26).   
Since Ex-527 was discovered, it has been used to examine for example the role of SIRT1 
in cell regulation as well as the role of SIRT1 in p53 acetylation and cell survival after DNA 
damage (26). 
 
 
Figure 3: Functions of SIRT1 (figure from 22) 
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The inhibition of SIRT1 is expected to occur by blocking NAD
+
 hydrolysis through binding 
to the NAD
+
 binding pocket (27). The inhibition with 1 µM EX-527 of SIRT1 catalytic activity had 
no effect on cell growth, viability or cell proliferation. (26). 
Resveratrol and SIRT1 
               The issues of which genes is particularly activated by resveratrol is sometimes 
controversial and hence, has been subject of numerous ongoing studies. Even though it in many 
years were considered a fact that resveratrol is activating SIRT1, Beher et al (2009) (28) showed 
that resveratrol does not active SIRT1 directly and suggests that AMPK* is the binding link. Park 
et al (2012) (29) did later identify the resveratrol-SIRT1 relation is acting via the Epac1-CamKKβ-
AMPK pathway.  
It has also been demonstrated in many scientific journals that resveratrol activates 
SIRT1 in the following phases: in heart cells and tissues of rodents (30), human epithelial cells 
(31) as well as bronchial epithelial cells (32). 
Several other observations suggest that a knockdown of SIRT1 partially suppresses the 
biological activities of resveratrol (33), (34). This may be an indication that SIRT1 is involved in 
cellular enlargement of resveratrol. 
Resveratrol, SIRT1 and mTOR 
The effect of resveratrol on mTOR signaling is mediated via SIRT1 genes (34). This is an 
indication that cellular activities of resveratrol passes through the SIRT1 cascade and not mTOR. 
This suggests that the signaling effect of resveratrol is dependent on SIRT1. That is, if SIRT1 is 
inhibited, resveratrol would not affect the mTOR signaling. 
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Results 
As explained earlier, the aim of our study is to examine the cellular effects of resveratrol 
on cell size with the modulating role by mTOR cascade and SIRT1 enzymes. Our results will give 
us information about the effect on the cell size when DLD-1 cells were treated with each 
substance, as well as the effect on cell proliferation.     
To investigate the role of mTOR activation by resveratrol in the resveratrol-mediated 
cell enlargement, we treated the cells with resveratrol (SIRT1 activator), rapamycin (mTOR 
inhibitor), or combination of resveratrol and rapamycin. After 48 hours of treatment the cell 
diameter was determined by coulter counter. Figure 4 shows the results of the experiment. The 
control (16.6 ∓ 0.4 µM) is used as the reference when comparing the effect of each substance. 
A 6 % increase in the mean cell diameter is found in 60 µM resveratrol (17.7∓2.8 µm). Each of 
the rapamycin treated cells mean values were smaller than the control, with 10% and 11.5% 
decrease with 0.5µM (14.9∓0.2 µm) and 0.25 µM (14.7∓0.2 µm) rapamycin respectively. The 
combinatory effect of 0.5 µM rapamycin and 60µM resveratrol (19.5∓0.4 µM) does increase 
the cell size by 18% which surprisingly is a bigger increase in the cell size than the 60µM 
resveratrol alone. This is surprising when you consider mTOR’s effect on the cell enlargement. 
The combinatory effect on the mean cell size of 0.25µM rapamycin and 60µM resveratrol 
(16.7∓1.9 µM) is found to be equal the control.  
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Rapamycin and Resveratrol 
 
Figure 4: Effect of resveratrol and rapamycin on cell diameter. Human colon cells (DLD-1) were 
treated with resveratrol (res), rapamycin (rap), or combination of resveratrol and rapamycin for 
48 h, and the cell diameter was determined by coulter counter. The data are mean values of 
four individual wells for each substance as well as their standard deviation (STD). This 
experiment has been performed once. 
 
Figure 5: Effect of resveratrol and rapamycin on cell number. 50000 human colon cells (DLD-1) 
were plated and treated with resveratrol (res), rapamycin (rap), or a combination of resveratrol 
and rapamycin for 48 h, and the amount of cells per mL was determined by coulter counter. 
These data are mean values of four individual wells for each substance as well as their standard 
deviation (STD).   
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 During the same experiment we investigated the role of mTOR activation by resveratrol 
on the cell number, the amount of cells per mL was determined by coulter counter. At the 
beginning of the experiment each well contained 50000 cells. Figure 5 displays the results. We 
used the control as a reference when comparing the effect of each substance on the cell 
number.  When the cells were treated with resveratrol a drastic decrease (54.5 %) in the cell 
number was observed. We also monitored the change in cell number when the cell were 
treated with rapamycin (inhibitor of mTOR), at the concentration 0.5 µM we found a 15 % 
decrease in the cell number while at concentration 0.25 µM rapamycin the cell amount were 
increased by 2 %. The combinatory effect of rapamycin and resveratrol on the cell were also 
monitored. Treatment with 0.5 µM rapamycin combined with 60 µM resveratrol reduced the 
amount of cells by 60 % while 0.25 µM rapamycin mixed with 60 µM resveratrol lessened the 
quantity of cells by 31.5%. 
 At the end of the experiment, pictures were taken of the cells (see figure 6). We see that 
they became larger in size when treated with both resveratrol and rapamycin, which 
corresponds to our calculations. 
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Figure 6: DLD-1 treated cells with resveratrol and rapamycin for 48 hours, in a 20X 
magnification using the same crop. These picture could perhaps say something about the 
turbulence of the treatment, and if they try to divide, or stays at the same cycle. 
 
  To investigate the role of SIRT1 activation by resveratrol in the resveratrol-mediated cell 
enlargement, we treated the cells with resveratrol (SIRT1 activator), EX-527 (SIRT1 inhibitor), or 
combination of resveratrol and EX-527. After 48 hours of treatment the cell diameter was 
determined by coulter counter. Figure 7 shows the results of the experiment. The control (15.2 
 0.2 µm) is used as the reference when comparing the effect of each substance. As expected 
60 µM resveratrol (19.3 1.2 µm) showed an increase in the cell size to be more precise a 27% 
increase was found. The mean values were also found for the inhibitor EX-527 at concentration 
300 nM (15.4 0.3 µm) and 150 nM (15.1 0.3 µm) respectively, both were found to be similar 
to the control. 300 nM EX-527 combined with 60 µM resveratrol (14.9  0.2 µm) showed no 
increase in the cell size, while 150 nM EX-527 combined with 60 µM resveratrol (16.8 3.6 µm) 
displayed a 10 % increase. 
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EX-527 and Resveratrol 
 
Figure 7: Effect of resveratrol and EX-527 on cell diameter. Human colon cells (DLD-1) were 
treated with resveratrol (res), EX-527, or combination of resveratrol and EX-527 for 48 h, and 
the cell diameter was determined by coulter counter. The data are mean values of four 
individual wells for each substance as well as their standard deviation (STD). This experiment 
has been performed once.  
 
 
Figure 8: Effect of resveratrol and EX-527 on cell number. 50000 human colon cells (DLD-1) 
were plated and treated with resveratrol (res), EX-527, or a combination of resveratrol and EX-
527 for 48 h, and the amount of cells per mL was determined by coulter counter. These data are 
mean values of four individual wells for each substance as well as their standard deviation 
(STD).   
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During the same experiment we investigated the role of SIRT1 activation by resveratrol 
on the cell number, the amount of cells per mL was determined by coulter counter. At the 
beginning of the experiment each well contained 50000 cells. Figure 8 displays the results. We 
used the control as a reference when comparing the effect of each substance on the cell 
number.  When the cells were treated with resveratrol a decrease of 23.5 % in the amount of 
cells were observed. The change in cell number when the cell were treated with EX-527 
(inhibitor of SIRT1) were also monitored, at the concentration 300 nM an 8 % increase while we 
at 150 nM EX-527 we observed an 11 % increase in the number of cells. The combinatory effect 
of EX-527 and resveratrol on the cell were also monitored. Treatment with 300 nM EX-527 
combined with 60 µM resveratrol reduced the amount of cells by 60 % while 150 nM EX-527 
mixed with 60 µM resveratrol lessened the quantity of cells by 75.5%. 
Figure 9 shows how the cells looked like after 48 hours of treatment. We clearly see that 
the combination of Resveratrol and EX-527 has been rough for these cells. 
 
Figure 9: DLD-1 treated cells with resveratrol and EX-527 for 48 hours, in a 20X magnification 
using the same crop. These picture could perhaps say something about the turbulence of the 
treatment, and if they try to divide, or stays at the same cycle 
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Discussion 
In our discussion we will see whether our hypothesis does match the results from our 
experiment, and thereby figure out if our model is correct, or not. We will also compare our 
results with previously published literature to see if there is a relation between the findings.  
From literature research we found that mTOR is tightly related to the cellular 
enlargement and in our results the inhibition of mTOR by rapamycin caused a smaller 
size/diameter in of the treated cells compared to the control. In the literature we also found 
that resveratrol is able to cause cells enlargement, and our results have shown the same.  
In our experiment we monitored the size change in DLD-1 cells with resveratrol, 
rapamycin (mTOR inhibitor) and EX-27 (SIRT1 inhibitor). All values are giving are mean values 
∓STD.   Treatment with rapamycin and resveratrol (19.5∓0.4 µm and 16.7∓1.9 µm for 0.5 µM 
rap + 60 µM res and 0.25 µM rap + 60µM res respectively) led to an 18% increase for the 
former while the later was equal to the control (16.6∓0.4 µm). While rapamycin on its own 
caused the cell size to decrease by 10 % (14.9∓0.2 µm) for 0.5 µM rapamycin and 11.5 % 
(14.7∓0.2 µm) for 0.25 µM rapamycin). The pure resveratrol treated cells showed an 6% 
increase in the cell size. This finding denies a proposed relation between mTOR and SIRT1 to be 
connected in an “axis” that affected the cell size. 
The EX-527 treatment with resveratrol may seem to have caused an increased cell size 
by 10 % at concentration 150 nM while it was prevented at 300 nM both combined with 60 µM 
resveratrol. But the increase in 150 nM is based on a single observation (23.0 µm, the others 
ranging 14.3-15.3µm) with mean 16.8∓3.6 µm, which skews the results from mean 14.7∓0.4 
µm without including this observation, with the control being at mean 15.2∓0.2 µm. Therefore 
we say that this point is an outliner and is therefore not taken into consideration.  
This is not the only interesting information our results have given us, as both 
experiments were carried out using the same methods and chemicals, we would expect the 
control and resveratrol values to be alike. However, this is not the case. In the rapamycin 
experiment the control was found to be 16.6∓0.4 µm while it in the EX-527 is 15.2∓0.2 µm 
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which equals an approximate 9 % difference. The same tendency is found in the numbers from 
60 µM resveratrol, where the obtained data of the EX-527 treatment show 19.3∓1.2 µm 
compared to 17.7∓2.8 µm which were found in the rapamycin experiment. This do of cause 
bring some questions on the strength of our results.  In order to bring down the difference 
more experiments would have to be done, creating a more stable control and resveratrol 
group.   
It is also interesting to see that both the controls got fairly low standard deviations (0.2 
and 0.4 µm), while they still are 9% different in the size. The resveratrol treatment is another 
story though, with the standard deviations being 1.2 and 2.8 µm, we can see that the cells 
which were exposed to the same treatment reacted differently, and therefore I consider this 
part of the results weak.  
On the other hand does the results from treatment with both inhibitors, indicate a high 
accuracy as none of our observation’s standard deviation raised above 0.3 µm, which is good. 
This part of the results I would consider strong.  
An important part, the combinatory effect, showed small standard deviations at their 
high inhibitor concentration (0.2 and 0.4 µm), while their low inhibitor concentration show 3.6 
and 1.9 µm (though if we outline the point as discussed earlier in the discussion, it would be 0.4 
and 1.9 µm). I would consider this part of the results weak.  
Now when the result discussion on the cell size has been done, a short discussion 
considering the cell number will be done too.  In the discussion of the cell size, we stated that 
the control and resveratrol treated cell is expected to act the same in both experiments, this 
counts for both cell size as well as the cell number. In the rapamycin treatment we observed 
118638 ∓30917 cells in the control, whereas we measured 135654∓40747 cells in the EX-
treatment, which equals a 13 % difference. In the rapamycin experiment we observed 
53993∓1852 (45.5% of the control) cells when the 50000 cells were treated with 60 µM 
resveratrol, while in the EX-527 treatment 103659∓8953 (76.4% of the control) cells were 
observed. When you compare them to their respective control, and subtract the numbers, the 
difference is 31%. When the cells were treated with rapamycin at concentration 0.5 µM, a 15 % 
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decrease in the cell size were observed, while at 0.25 µM the rapamycin had no effect on the 
cell number. 0.25 µM rapamycin having less effect than 0.5 µM in the combinatory effect, with 
22% decrease versus a 60 % decrease.  
The combinatory effect of EX-527 and resveratrol caused the cell number to decrease 
drastically to 40 % and 35 % for 300 nM and 150 nM EX-527 respectively. While the EX-527 
alone resulted in a 9% increase for 300 nM EX-527, there was observed a 12 % increase in the 
cell number when the cells were treated with 150 nM EX-527.     
Based on our results we can conclude that SIRT1 plays a big role in the cell enlargement, 
either in a direct connection or through activation of a third gene.    
Through our results we will evaluate our hypothesis. The results of our experiments 
seem to deviate from our initial hypothesis – that resveratrol acts on mTOR cascade through 
SIRT1. This was also suggested by Ghosh et al. (2010) (35) but we found that the cells continued 
to increase in size even after mTOR got inhibited. This suggests that mTOR may not be solely 
responsible for cellular enlargement. 
However, our results do support another suggestion from Ghosh et al. (2010) (35) that 
resveratrol activates SIRT1.  We showed this by inhibiting SIRT1 with a combination of EX-527 
while added 60 µM resveratrol and compared with the 60 µM resveratrol treated cell (detailed 
discussion earlier in this section). This showed evidently that resveratrol’s effect on the cellular 
enlargement was hindered when SIRT1 was inhibited.   
Our report does not suggest that SIRT1 down regulate the mTOR activities as proposed 
by Ghosh et al. (2010) (35). We suggest that SIRT1 might increase the cell size directly or 
indirectly without involving mTOR (Figure 10).  
However, we are aware of the fact that the results of our experiments are based on 
non-expert knowledge. Our experiments were not repeated due to time shortage and this may 
have some effects on the results as we are aware that repetition can minimize possible errors. 
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Figure 10: The possible connections that have partially been cleared via our results.  
As we haven’t repeated this experiment, the accuracy of our results is not sufficient, and therefore this 
study cannot be classified as empirical evidence.  Further work will be required in order to prove this 3rd 
gene factor. 
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Conclusion and Perspective  
 
First we believed that resveratrol was acting on mTOR cascade through SIRT1. This 
means that we suspected that resveratrol`s involvement in cellular enlargement is being 
mediated via SIRT1 before reaching the mTOR, in the following pathway: resveratrol->SIRT1-
>mTOR-> cellular enlargement. We wanted to prove this by applying some well-known 
inhibitors of mTOR and SIRT1, rapamycin and EX-527 respectively. After our experiment we 
came to the following conclusions:  
1), that resveratrol has no direct or indirect action on mTOR. This conclusion is based on 
the inhibition of mTOR. When we treated the cells with a combination of rapamycin and 
resveratrol, we observed a continuing increase in the cell size. This is an indication that the cell 
size is solely mediated via SIRT1 enzyme and not via the mTOR. 
2) SIRT1 is either itself causing cellular enlargement or is activating a third gene which 
increases the cell size. This was shown when we treated the cells with resveratrol and inhibited 
the SIRT1, which caused the cells to cease the cell enlargement process of resveratrol.  
Before our experiments we believed that mTOR is solely responsible for cell growth and 
proliferation but our results indicate that a third gene which is possible activated by SIRT1 may 
be involved. In this case, we suggest that it would be interesting to investigate the role of other 
cellular proteins/enzymes, with the purpose of finding out which gene(s) is possibly being 
activated by SIRT1. 
 We suggest repeating these experiments should be repeated in order to minimize and 
eliminate possible errors.    
Even though there may be possible experimental error(s), our results might present new 
information that could be interesting for further researches. 
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Materials and Methods 
Medium, compounds and molecules 
Gentamicin and Trypsin from Gibco, Rapamycin and poly-l-lysine from Sigma –Aldrich. 
And NaCl (most suitable according to our experiment), McCoy 5A (OMB275) Media w. 
GlutaMAX (10%PBS) D-PBS. 10% FBS (0739L), gentamycin (92274). 
A stock solution of 600 mM resveratrol dissolved in DMSO, stored at -18
o
C. Resveratrol 
was then diluted to a desired concentration of 60 µM. We diluted our rapamycin to 0.5 as well 
as 0.25 µM from a stock solution as both concentrations were used in the experiment. EX-527 
concentrations of 300 nM and 150 nM were diluted from a stock solution, prepared at -18
o
C. 5, 
10 and 25 ml pippet (glass). Multi and single pipetting tools. 
Software and instruments: 
Coulter counter, particle count and size analyser Z2 (from Beckman coulter Inc). Phase 
contract microscope: Leica DM IRA witleica DC 300F cam. Microsoft Excel macro document and 
a java script “FitterBJ03” provided by Ole Vang. 
Cell culture: 
The cells used in our experiment were DLD-1 (human epithelial colon cancer) cells.  
These cells were prepared in culture flask in a McCoy media with 10% Fetal Bovine Serum 
included and kept at 37
o
C, 95% humidity and 5% CO2. These cells were about 50 – 75% 
confluent and were cultivated 2 times a week. We counted the cells before and after the 
experiments in coulter counter machine. During the counting the cells were kept in ice during 
the experiments. 
Preparation of samples: 
We made sure that we marked the cover slips of our cells for an easy identification. The 
cells were then transferred to an incubating machine for around 5-8 minutes after 
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trypsinization to enable the cells detach (enhance adhesion) from the base of the well plate. 
After incubation, we placed the cells under the microscope to monitor the level of detachment, 
if the detachment is fine, we continue with addition of media, and then re-suspend the cells by 
pipetting up and down to allow maximum separation of cells. We then remove approx. 9.5 ml 
of the medium and add 12 ml of fresh medium from which we take 1 ml for cell counting. The 
desired cell number before counting is 50,000 cells/1ml. 
Resveratrol, rapamycin and EX-527 treatment: 
The treatment with resveratrol and rapamycin lasted for 48 hours. We washed the cells 
(with trypsin) and added fresh media (FBS), and then we diluted both the resveratrol and 
rapamycin from the stock concentration to the desired concentration and added them to the 
cell culture. After 48 hours of incubation, we took phase contrast images of the cells with the 
aid of a microscope. Pictures were taking in different magnifications of 10 and 20 times 
magnification to enable the best possible comparison. The same process was followed during 
our resveratrol – EX-527 experiment. 
Images: 
Pictures obtained from the microscope were compared and analyzed. The difference in 
cell sizes tells us whether the cells have grown within the incubation period or not. 
Furthermore, the color of the cells was also very critical as this was used to find out whether 
the cells are dying after treatment or not. It also gave us some clues as to the quantity of the 
dying cells.  
Excel software:  
We used an Excel macro in order to clarify the obtained results. With this software, we 
were able to measure changes in the cell diameters and numbers, which helped us, understand 
the direction(s) of our results. The software was provided by our supervisor (Ole Vang).  
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Transformation of raw data: 
Multisizer were used to transform the data, it counted cell size and numbers, which 
were transferred into excel.  We operated an excel macro document called “Coulter AccuComp 
Import Master UK” and the javascript “FitterBJ03” to calculate the means and peak value. 
Precaution: 
We were aware before our experiments that we have to follow the necessary 
experimental procedures laid down by lab experts to minimize experimental error(s). This was 
one of the reasons why we spent our first day in the lab learning how to handle the lab tools 
and chemicals.  This study’s experiments were carried out in a sterile environment.  
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Glossary  
 
Actins:  A muscle protein localized in the I band of the myofibrils.  
 
Adenocarcinoma: Adenocarcinoma is a cancer originating in glandular tissue. 
Akt/PKB:  Is a specific protein that plays a key role in multiple cellular processes such 
as glucose metabolism, apoptosis, cell proliferation, transcription and cell 
migration. 
AMPK: AMP-activated protein kinase.  
Anabolic process: The phase of metabolism in which simple substances are 
synthesized into the complex materials of living tissue. 
Apoptosis: Programmed cell death. 
Atherogenesis: Formation of abnormal fatty or lipid masses in arterial walls. 
Autophagy: Also called autophagocytosis, is a catabolic process that breaks down the 
cell’s own components, through lysosomes. 
Catabolic process: The metabolic breakdown of complex molecules into simpler ones, 
often resulting in a release of energy. 
Deacetylation: Is the removal of the acetyl group, and preventing it from reacting 
with other chemical group, deacetylation in this biological form, is a post-
translational modification of a protein. 
DLD-1: Epithelial cell in the “Human colon adenocarcinoma”. 
Epithelial tissue: The whole surface of the body is called epithelial tissue (epithelium). 
The epithelium is made of tight packed cells ranged in one or many layers. Forms 
all internal and external body surfaces. 
Lysosome: Cellular organelles that break down waste materials, other organelles and 
components, inside the cell. 
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mTOR (Mammalian Target of Rapamycin): Organized in two different catalytic   
subunits (mTORC1 and mTORC2). 
NAD
+
: Nicotinamide adenine dinucleotide 
P53: Tumor suppressing gene. 
Phytoalexin: Antimicrobial substance produced by plants. 
Senescence: Also called biological aging, is a change in the organism after its 
maturity. 
SIRT1: Silent Information Regulator 
STD: Standard deviation 
 
 
 
 
 
 
